Evidence map›Paper›PMID 36241691›Full record

ArticleScientific reports2022

Profile of gut microbiota and serum metabolites associated with metabolic syndrome in a remote island most afflicted by obesity in Japan.

Tsugumi Uema, Jasmine F Millman, Shiki Okamoto, Takehiro Nakamura, Kiyoto Yamashiro, Moriyuki Uehara, Ken-Ichiro Honma, Minoru Miyazato, Asuka Ashikari, Seiichi Saito and 6 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 1 institution in 1 country.

Tsugumi UemaDivision of Endocrinology, Diabetes and Metabolism, Hematology, Rheumatology, (Second Department of Internal Medicine), Graduate School of Medicine, University of the Ryukyus, 207 Uehara, Nishihara, Okinawa, 903-0215, Japan.
Jasmine F MillmanDivision of Endocrinology, Diabetes and Metabolism, Hematology, Rheumatology, (Second Department of Internal Medicine), Graduate School of Medicine, University of the Ryukyus, 207 Uehara, Nishihara, Okinawa, 903-0215, Japan. Jasmine.f.millman@gmail.com.ORCID 0000-0001-7049-3881
Shiki OkamotoDivision of Endocrinology, Diabetes and Metabolism, Hematology, Rheumatology, (Second Department of Internal Medicine), Graduate School of Medicine, University of the Ryukyus, 207 Uehara, Nishihara, Okinawa, 903-0215, Japan. shiki@med.u-ryukyu.ac.jp.ORCID 0000-0002-2802-0527
Takehiro NakamuraDivision of Endocrinology, Diabetes and Metabolism, Hematology, Rheumatology, (Second Department of Internal Medicine), Graduate School of Medicine, University of the Ryukyus, 207 Uehara, Nishihara, Okinawa, 903-0215, Japan.
Kiyoto YamashiroDivision of Endocrinology, Diabetes and Metabolism, Hematology, Rheumatology, (Second Department of Internal Medicine), Graduate School of Medicine, University of the Ryukyus, 207 Uehara, Nishihara, Okinawa, 903-0215, Japan.
Moriyuki UeharaDivision of Endocrinology, Diabetes and Metabolism, Hematology, Rheumatology, (Second Department of Internal Medicine), Graduate School of Medicine, University of the Ryukyus, 207 Uehara, Nishihara, Okinawa, 903-0215, Japan.
Ken-Ichiro HonmaDivision of Endocrinology, Diabetes and Metabolism, Hematology, Rheumatology, (Second Department of Internal Medicine), Graduate School of Medicine, University of the Ryukyus, 207 Uehara, Nishihara, Okinawa, 903-0215, Japan.
Minoru MiyazatoDepartment of Systems Physiology, Graduate School of Medicine, University of the Ryukyus, Uehara, Nishihara, Okinawa, Japan.
Asuka AshikariDepartment of Urology, Graduate School of Medicine, University of the Ryukyus, Uehara, Nishihara, Okinawa, Japan.
Seiichi SaitoDepartment of Urology, Graduate School of Medicine, University of the Ryukyus, Uehara, Nishihara, Okinawa, Japan.
Shiro MaedaDepartment of Advanced Genomic and Laboratory Medicine, Graduate School of Medicine, University of the Ryukyus, Uehara, Nishihara, Okinawa, Japan.
Minako ImamuraDepartment of Advanced Genomic and Laboratory Medicine, Graduate School of Medicine, University of the Ryukyus, Uehara, Nishihara, Okinawa, Japan.
Hajime IshidaDepartment of Human Biology and Anatomy, Graduate School of Medicine, University of the Ryukyus, Uehara, Nishihara, Okinawa, Japan.
Masayuki MatsushitaDepartment of Molecular and Cellular Physiology, Graduate School of Medicine, University of the Ryukyus, Uehara, Nishihara, Okinawa, Japan.
Koshi NakamuraDepartment of Public Health and Hygiene, Graduate School of Medicine, University of the Ryukyus, Uehara, Nishihara, Okinawa, Japan.
Hiroaki MasuzakiDivision of Endocrinology, Diabetes and Metabolism, Hematology, Rheumatology, (Second Department of Internal Medicine), Graduate School of Medicine, University of the Ryukyus, 207 Uehara, Nishihara, Okinawa, 903-0215, Japan. hiroaki@med.u-ryukyu.ac.jp.ORCID 0000-0002-2445-1047
University of the Ryukyus · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Numerous studies have revealed distinct differences in the profiles of gut microbiota between non-obese and obese individuals. To date, however, little is known if any disparities in the community of gut microbiota exist between metabolically healthy obese (MHO) and metabolically unhealthy obese (MUO) subjects. We therefore aimed to comprehensively characterize the gut microbiota and circulating metabolites in serum from both MHO and MUO residing in the remote island, Kumejima, where the prevalence of obesity is one of the highest in Japan, and explored possible correlations between the gut microbiota profile and markers of metabolic syndrome. Results revealed that MUO showed significantly higher levels of genera such as g_Succinivibrio, g_Granulicatella, g_Brachyspira, g_Oribacterium and g_Atopobium in comparison to MHO. Moreover, abundance of g_Succinivibrio, g_Brachyspira and g_Atopobium were positively correlated with value of fasting insulin, HOMA-R, circulating triglycerides, diastolic blood pressure, BMI, body weight, waist circumference and HbA1c. In addition, MUO compared to MHO showed an imbalance of serum metabolites, with a significant elevation in 2-oxoisovaleric acid, pyruvic acid, 2-hydroxybutyric acid, and creatine. Our data highlight unmet needs in precision approaches for the treatment of obesity, targeting the gut microbiota profile and serum metabolites in a distinct population affected by obesity.

Indexed as

Gastrointestinal MicrobiomeInsulinsMetabolic SyndromeBody Mass IndexCreatineGlycated HemoglobinHumansJapanObesityPyruvic AcidTriglyceridesCreatineGlycated HemoglobinInsulinsPyruvic AcidTriglycerides

Identifiers

PMID36241691
PMCPMC9568508
OpenAlexW4306194501

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.